$RAPH
Raphael Pharmaceutical Inc. Stock $raph

$raph Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023022628 Filed on March 24, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$144.0K	$428.0K
YoY Change
% of Gross Profit
Research & Development	$114.0K	$676.0K	$1.178M
YoY Change	32.56%		51.03%
% of Gross Profit
Depreciation & Amortization	$1.000K		$0.00
YoY Change
% of Gross Profit
Operating Expenses	$114.0K	$1.104M	$1.178M
YoY Change	32.56%		-27.73%
Operating Profit	-$258.0K		-$3.317M
YoY Change	47.43%		103.62%
Interest Expense	-$6.000K	$1.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$6.000K		-$41.00K
YoY Change	-40.0%		-920.0%
Pretax Income	-$264.0K	-$1.103M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$264.0K	-$1.103M	-$3.358M
YoY Change	42.7%		106.01%
Net Earnings / Revenue
Basic Earnings Per Share	$0.02		$0.23
Diluted Earnings Per Share	$0.02	-$0.07	$0.23
COMMON SHARES
Basic Shares Outstanding	16.14M shares	15.62M shares	14.34M shares
Diluted Shares Outstanding	15.96M shares		14.34M shares

Balance Sheet

Concept	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.00K	$288.0K
YoY Change
Cash & Equivalents	$38.00K	$288.0K
Short-Term Investments
Other Short-Term Assets	$111.0K	$43.00K
YoY Change		-84.01%
Inventory
Prepaid Expenses		$5.000K
Receivables
Other Receivables
Total Short-Term Assets	$149.0K	$331.0K
YoY Change		-21.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000K	$2.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.000K	$2.000K
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$149.0K	$331.0K
Total Long-Term Assets	$1.000K	$2.000K
Total Assets	$150.0K	$333.0K
YoY Change		-21.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$147.0K	$224.0K
YoY Change
Accrued Expenses		$152.0K
YoY Change		-7.88%
Deferred Revenue
YoY Change
Short-Term Debt	$12.00K	$3.000K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$159.0K	$227.0K
YoY Change		-22.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$159.0K	$227.0K
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$159.0K	$227.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$6.289M	-$6.025M
YoY Change		125.91%
Common Stock	$160.0K	$157.0K
YoY Change		20.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.000K	$106.0K
YoY Change
Total Liabilities & Shareholders Equity	$150.0K	$333.0K
YoY Change		-21.09%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$264.0K	-$1.103M	-$3.358M
YoY Change	42.7%		106.01%
Depreciation, Depletion And Amortization	$1.000K		$0.00
YoY Change
Cash From Operating Activities	-$399.0K	-$277.0K	-$759.0K
YoY Change	386.59%		-46.55%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$2.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	-$2.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$149.0K	472.0K	$896.0K
YoY Change	1390.0%		-39.46%
NET CHANGE
Cash From Operating Activities	-$399.0K	-277.0K	-$759.0K
Cash From Investing Activities		0.000	-$2.000K
Cash From Financing Activities	$149.0K	472.0K	$896.0K
Net Change In Cash	-$250.0K	195.0K	$135.0K
YoY Change			125.0%
FREE CASH FLOW
Cash From Operating Activities	-$399.0K	-$277.0K	-$759.0K
Capital Expenditures		$0.00	$2.000K
Free Cash Flow	-$399.0K	-$277.0K	-$761.0K
YoY Change	386.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-53002
CY2022	dei	Entity Registrant Name EntityRegistrantName	Raphael Pharmaceutical Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0204284
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Lui Paster
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv-Jaffa
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6803605
CY2022	dei	City Area Code CityAreaCode	(972)
CY2022	dei	Local Phone Number LocalPhoneNumber	52-775-5072
CY2022	dei	Security12g Title Security12gTitle	Common Stock, $0.01 par value
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16135790	shares
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co
CY2022	dei	Auditor Firm AuditorFirmId	6629
CY2022	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	43000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	269000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	331000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	422000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2000	usd
CY2022Q4	us-gaap	Assets Assets	333000	usd
CY2021Q4	us-gaap	Assets Assets	422000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	224000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	272000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	3000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	22000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	227000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	294000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15624040	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15624040	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12970540	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12970540	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	157000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	130000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5974000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2665000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6025000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2667000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	106000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	128000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	333000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	422000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1178000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	776000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2139000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	853000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3317000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1629000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3358000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1624000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14341518	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11171704	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	128000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	893000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2443000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3358000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-43000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1289000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	506000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1624000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	128000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3358000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1624000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2290000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-226000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	41000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-19000	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	13000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	102000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	234000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-759000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1418000	usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	2000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	174000	usd
CY2022	cik0000141539	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	896000	usd
CY2021	cik0000141539	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1289000	usd
CY2021	cik0000141539	Cash Acquired In The Reverse Recapitalization CashAcquiredInTheReverseRecapitalization	13000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	896000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1476000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	135000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	58000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	288000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	153000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	150000	usd
CY2022	cik0000141539	Non Cash Issuance Costs NonCashIssuanceCosts	70000	usd
CY2021	cik0000141539	Non Cash Issuance Costs NonCashIssuanceCosts	102000	usd
CY2021	cik0000141539	Current Assetsexcluding Cash And Cash Equivalents CurrentAssetsexcludingCashAndCashEquivalents	-531000	usd
CY2021	cik0000141539	Current Liabilities CurrentLiabilities	38000	usd
CY2021	cik0000141539	Reverse Recapitalization Effect On Equity ReverseRecapitalizationEffectOnEquity	506000	usd
CY2021	cik0000141539	Cash Acquired In Connection With Reverse Recapitalization Transaction CashAcquiredInConnectionWithReverseRecapitalizationTransaction	13000	usd
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021.
CY2021Q2	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	100	shares
CY2021Q2	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	9459253	shares
CY2021Q2	cik0000141539	Issued And Outstanding Share Capital Percentage IssuedAndOutstandingShareCapitalPercentage	0.90	pure
CY2021Q2	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	1051028	shares
CY2021Q2	cik0000141539	Common Stock Percentage CommonStockPercentage	0.10	pure
CY2022Q4	cik0000141539	Accumulated Deficit AccumulatedDeficit	6025000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3358000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-759000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 67px"> </td> <td style="width: 29px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimate in preparation of financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-indent: -1cm"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify"> </p>
CY2022Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	1000	usd
CY2022	cik0000141539	Milestone Payment1 MilestonePayment1	1400000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3358000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1624000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14341518	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11171704	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2022	cik0000141539	Net Sales Percenage NetSalesPercenage	0.06	pure
CY2022	us-gaap	Payments For Fees PaymentsForFees	1150000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	100000	usd
CY2022Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	38000	usd
CY2021Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	92000	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	5000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	177000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	43000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	269000	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	72000	usd
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	107000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	152000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	165000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	224000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	272000	usd
CY2022Q4	cik0000141539	Total Cost Description TotalCostDescription	Total cost of the new study will be $800 + $160 (overhead) + VAT (which consist of $700 + VAT pre-clinical lab research cost, $120 + VAT Mouse model for systemic inflammation and $140 + VAT Mouse model for Rheumatoid Arthritis).
CY2022	us-gaap	Public Utilities Approved Equity Capital Structure Percentage PublicUtilitiesApprovedEquityCapitalStructurePercentage	0.03	pure
CY2022	cik0000141539	Cash Payment CashPayment	100000	usd
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.15	pure
CY2019Q2	cik0000141539	Remaining Services Fee RemainingServicesFee	10000	usd
CY2022	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	1.12
CY2022Q4	us-gaap	Liabilities Subject To Compromise Early Contract Termination Fees LiabilitiesSubjectToCompromiseEarlyContractTerminationFees	360000	usd
CY2022Q4	us-gaap	Compensation And Benefits Trust CompensationAndBenefitsTrust	12000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1000000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1000000	shares
CY2022	cik0000141539	Royalty Percentage1 RoyaltyPercentage1	0.15	pure
CY2022	cik0000141539	Companys Net Royalties Percentage CompanysNetRoyaltiesPercentage	0.15	pure
CY2021Q1	cik0000141539	Company Raised Amount CompanyRaisedAmount	578000	usd
CY2021Q3	cik0000141539	Company Raised Amount CompanyRaisedAmount	578000	usd
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	52000	usd
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1632509	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9459253	shares
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	102000	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70000	shares
CY2022Q2	cik0000141539	Purchase Warrants PurchaseWarrants	100000	shares
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.5
CY2022Q2	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	550000	usd
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	70000	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	250000	shares
CY2022Q2	cik0000141539	Purchase Warrants PurchaseWarrants	100000	shares
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.13
CY2022Q2	cik0000141539	Companys Service Provider Consideration Of Past Services CompanysServiceProviderConsiderationOfPastServices	250000	usd
CY2022Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2022Q2	cik0000141539	Company Raised Amount CompanyRaisedAmount	50000	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	280000	shares
CY2022Q2	cik0000141539	Purchase Warrants PurchaseWarrants	105000	shares
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.12
CY2022Q2	cik0000141539	Service Fees ServiceFees	290000	usd
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100500	shares
CY2022Q3	cik0000141539	Service Fees ServiceFees	100000	usd
CY2022Q3	us-gaap	Shares Issued SharesIssued	102000	shares
CY2022Q3	cik0000141539	Service Fees ServiceFees	100000	usd
CY2022Q4	cik0000141539	Company Raised Amount CompanyRaisedAmount	50000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50000	shares
CY2022Q4	cik0000141539	Purchase Warrants PurchaseWarrants	50000	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.4
CY2022Q4	us-gaap	Shares Issued SharesIssued	90000	shares
CY2022Q4	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	90000	shares
CY2022Q4	cik0000141539	Company Raised Amount CompanyRaisedAmount	100000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80000	shares
CY2022Q4	cik0000141539	Purchase Warrants PurchaseWarrants	20000	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.5
CY2022Q4	cik0000141539	Company Raised Amount CompanyRaisedAmount	20000	usd
CY2022Q4	cik0000141539	Purchase Warrants PurchaseWarrants	47250	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.25
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4461250	shares
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	3000	usd
CY2021Q4	us-gaap	Other Notes Payable OtherNotesPayable	22000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	3000	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	22000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	113000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	120000	usd
CY2022	cik0000141539	Chief Executive Officer Fee ChiefExecutiveOfficerFee	72000	usd
CY2021	cik0000141539	Chief Executive Officer Fee ChiefExecutiveOfficerFee	75000	usd
CY2022	cik0000141539	Chief Technology Officer Fee ChiefTechnologyOfficerFee	105000	usd
CY2021	cik0000141539	Chief Technology Officer Fee ChiefTechnologyOfficerFee	115000	usd
CY2022	cik0000141539	Directors Fee1 DirectorsFee1	17000	usd
CY2021	cik0000141539	Directors Fee1 DirectorsFee1	36000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2090000	usd
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2397000	usd
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	346000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.21	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.80	pure
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5746000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1243000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1243000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3358000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1624000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	705000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	341000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-705000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-341000	usd
CY2022	cik0000141539	Subcontractors And Consultants1 SubcontractorsAndConsultants1	551000	usd
CY2021	cik0000141539	Subcontractors And Consultants1 SubcontractorsAndConsultants1	765000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	600000	usd
CY2022	cik0000141539	Laboratory Services LaboratoryServices	27000	usd
CY2021	cik0000141539	Laboratory Services LaboratoryServices	11000	usd
CY2022	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	1178000	usd
CY2021	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	776000	usd
CY2022	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	289000	usd
CY2021	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	697000	usd
CY2022	cik0000141539	Share Based Compensation1 ShareBasedCompensation1	1690000	usd
CY2022	cik0000141539	Consulting Services ConsultingServices	113000	usd
CY2021	cik0000141539	Consulting Services ConsultingServices	120000	usd
CY2022	us-gaap	Cost Maintenance CostMaintenance	9000	usd
CY2021	us-gaap	Cost Maintenance CostMaintenance	31000	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	38000	usd
CY2021	us-gaap	Other General Expense OtherGeneralExpense	5000	usd
CY2022	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	2139000	usd
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	853000	usd
CY2022	cik0000141539	Bank Fees BankFees	3000	usd
CY2021	cik0000141539	Bank Fees BankFees	2000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	38000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-7000	usd
CY2022	cik0000141539	Total Financial Expenses Net TotalFinancialExpensesNet	41000	usd
CY2021	cik0000141539	Total Financial Expenses Net TotalFinancialExpensesNet	-5000	usd
CY2022Q4	cik0000141539	Agreement Amount AgreementAmount	7.5	usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	6000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	18000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.25
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
CY2022	cik0000141539	Cash Acquired In The Reverse Recapitalization CashAcquiredInTheReverseRecapitalization		usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	cik0000141539	Current Assetsexcluding Cash And Cash Equivalents CurrentAssetsexcludingCashAndCashEquivalents		usd
CY2022	cik0000141539	Current Liabilities CurrentLiabilities		usd
CY2022	cik0000141539	Reverse Recapitalization Effect On Equity ReverseRecapitalizationEffectOnEquity		usd
CY2022	cik0000141539	Cash Acquired In Connection With Reverse Recapitalization Transaction CashAcquiredInConnectionWithReverseRecapitalizationTransaction		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14341518	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards		usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions		usd
CY2021	cik0000141539	Share Based Compensation1 ShareBasedCompensation1		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001415397
CY2022Q2	dei	Entity Public Float EntityPublicFloat	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	21020560	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	21020560	shares

Files In Submission

Name	View Source	Status
0001213900-23-022628-index-headers.html	Edgar Link	pending
0001213900-23-022628-index.html	Edgar Link	pending
0001213900-23-022628.txt	Edgar Link	pending
0001213900-23-022628-xbrl.zip	Edgar Link	pending
cik0000141539-20221231.xsd	Edgar Link	pending
f10k2022ex31-1_raphael.htm	Edgar Link	pending
f10k2022ex31-2_raphael.htm	Edgar Link	pending
f10k2022ex32-1_raphael.htm	Edgar Link	pending
f10k2022ex32-2_raphael.htm	Edgar Link	pending
f10k2022_raphaelpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
cik0000141539-20221231_cal.xml	Edgar Link	unprocessable
cik0000141539-20221231_def.xml	Edgar Link	unprocessable
cik0000141539-20221231_pre.xml	Edgar Link	unprocessable
cik0000141539-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_raphaelpharma_htm.xml	Edgar Link	completed
fin_002.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RAPH
Raphael Pharmaceutical Inc. Stock $raph

2023 Q1 Form 10-K Financial Statement

#000121390023022628 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RAPH Raphael Pharmaceutical Inc. Stock $raph

2023 Q1 Form 10-K Financial Statement

#000121390023022628 Filed on March 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RAPH
Raphael Pharmaceutical Inc. Stock $raph